CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Market News National Biologics Manufacturing Centre launched
News
1 Oct 2015

National Biologics Manufacturing Centre launched

The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.

The Centre for Process Innovation (CPI) has officially launched the new £38 million National Biologics Manufacturing Centre in Darlington, Co. Durham. The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.

Biopharmaceuticals are medicines produced through biotechnology, which represent the cutting-edge The National Biologics Manufacturing Centre was announced in 2012 as part of the UK strategy for life science. The strategy outlined a vision for the UK to be a global leader in the life science sector. The £38 million investment was made by the Department for Business Innovation and Skills through InnovateUK.

Launching the new Centre, Jo Johnson MP, Minister of State for Universities and Science said: “We want the UK to be the best place in Europe to innovate which is why we have invested in this new Centre to capitalise on the North East’s expertise in medicines manufacturing and strengthen the UK’s position as a global leader in life sciences. As part of our successful Catapult network, the centre will bridge the gap between business and academia and help to turn great ideas into commercial reality.”

Steve Bagshaw, CEO of FUJIFILM Diosynth Biotechnologies said: “The National Biologics Manufacturing Centre will provide a valuable resource for the biologics sector in the UK. The centre will help the UK capture more of the expanding global market in high value, high quality manufacture of biologic medicines and make an important contribution to equipping the UK workforce to meet the challenges faced in this sector”.

  • Nigel Perry, CEO of CPI said, “The launch of the National Biologics Manufacturing Centre will significantly increase the UK’s manufacturing capability in biologics and strengthen the UK’s position as the location of choice for life science companies. This open access facility will enable companies to test and trial new ideas cheaply and quickly with minimised risk, allowing new innovative medicines to reach the market faster and provide improved care for patients and better opportunities for businesses.”

    Chris Dowle, Director of Biologics at CPI added: “CPI is supporting the commercialisation of research by promoting collaboration with industry across the supply chain, from research through to manufacture and clinic. Utilising the new Centre we will help companies to commercialise ideas and take them to market faster and with less risk. We are already underway with a number of projects which are helping UK companies prove their technologies in an industrially relevant environment.”

    Ruth McKernan, Chief Executive of Innovate UK, said: “This new biologics manufacturing facility will be an important addition to CPI’s world-class capabilities in high value manufacturing. It will also work closely with our ground-breaking three healthcare Catapults and keep the UK at the forefront of a sector we have long excelled in.”

    • Related tags
    Market Top Stories

    Related News